Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
| ▸ | ATF1 | P18846 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783131 | 0.92 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2CSF1REPHX2 | |
| SCHEMBL5780199 | 0.92 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2CSF1RMEN1 | |
| SCHEMBL5777684 | 0.89 | TP53 (0.47) | NPC1RAB9ASMN1; SMN2CSF1RMEN1 | |
| SCHEMBL5779154 | 0.88 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2CSF1RTGM2 | |
| SCHEMBL5779995 | 0.86 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2CSF1REPHX2 | |
| SCHEMBL5781453 | 0.83 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2NAMPTMAPT | |
| SCHEMBL5489392 | 0.82 | MAPT (0.43) | NPC1RAB9ASMN1; SMN2CSF1REPHX2 | |
| SCHEMBL5779444 | 0.82 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2CSF1REPHX2 | |
| SCHEMBL5778499 | 0.81 | TP53 (0.47) | NPC1RAB9ASMN1; SMN2CSF1RMEN1 | |
| SCHEMBL5779748 | 0.79 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2TGM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | claimed |
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-07-01 | — | — | US | claimed |
| EP-1383757-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | claimed |
| WO-2002081463-A1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1383757-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2006-09-27 | — | — | EP | disclosed |
| US-6998407-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-6677365-B2 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE; RHEUMATIC DISEASES; CARDIOVASCULAR DISORDERS | TELIK, INC. | 2004-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127513-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | NPC1 689/4885RAB9A 3041/4885SMN1; SMN2 3130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.